IBNSINA PHARMA |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.55 EGP | 0.00% |
|
-6.25% | -18.79% |
| May. 19 | Ibnsina Pharma Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Mar. 03 | Ibnsina Pharma Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 8,011 | 4,886 | 3,907 | 2,419 | 3,517 | 2,570 | - | - |
| Enterprise Value (EV) 1 | 8,932 | 5,829 | 5,724 | 5,781 | 7,204 | 6,219 | 6,012 | 5,836 |
| P/E ratio | - | 26.8 x | 15.7 x | 16.6 x | 18.5 x | 7.97 x | 5.2 x | 3.19 x |
| Yield | 0.71% | - | 2.47% | - | - | 1.06% | 1.65% | - |
| Capitalization / Revenue | 0.48 x | 0.26 x | 0.18 x | 0.11 x | 0.1 x | 0.07 x | 0.05 x | 0.04 x |
| EV / Revenue | 0.54 x | 0.31 x | 0.26 x | 0.26 x | 0.21 x | 0.17 x | 0.12 x | 0.1 x |
| EV / EBITDA | 11.9 x | 8.46 x | 6.79 x | 6.96 x | 5.03 x | 3.92 x | 2.93 x | 2.44 x |
| EV / FCF | -23.6 x | 16.3 x | -11.7 x | - | -31.6 x | 9.73 x | 6.68 x | 4.89 x |
| FCF Yield | -4.24% | 6.14% | -8.52% | - | -3.17% | 10.3% | 15% | 20.4% |
| Price to Book | 7.1 x | 3.58 x | 3.13 x | 1.73 x | 2.18 x | 1.54 x | 1.2 x | 0.82 x |
| Nbr of stocks (in thousands) | 1,119,994 | 1,119,994 | 1,119,994 | 1,120,000 | 1,120,000 | 1,008,000 | - | - |
| Reference price 2 | 7.153 | 4.363 | 3.489 | 2.160 | 3.140 | 2.550 | 2.550 | 2.550 |
| Announcement Date | 2/25/20 | 3/1/21 | 3/23/22 | 3/1/23 | 3/3/24 | - | - | - |
1EGP in Million2EGP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 16,600 | 18,679 | 21,733 | 22,264 | 33,949 | 36,644 | 48,928 | 57,518 |
| EBITDA 1 | 750.4 | 689 | 842.8 | 830.5 | 1,432 | 1,587 | 2,048 | 2,387 |
| EBIT 1 | 653.3 | 530.2 | 709.5 | 652.4 | 1,312 | 1,633 | 1,963 | - |
| Operating Margin | 3.94% | 2.84% | 3.26% | 2.93% | 3.86% | 4.46% | 4.01% | - |
| Earnings before Tax (EBT) 1 | 420.9 | 292.2 | 425.3 | 175.3 | 268 | 345 | 547 | - |
| Net income 1 | 328.8 | 224.7 | 314.7 | 172.6 | 213.7 | 417 | 527 | 887 |
| Net margin | 1.98% | 1.2% | 1.45% | 0.78% | 0.63% | 1.14% | 1.08% | 1.54% |
| EPS 2 | - | 0.1629 | 0.2229 | 0.1300 | 0.1700 | 0.3200 | 0.4900 | 0.8000 |
| Free Cash Flow 1 | -378.3 | 357.9 | -488 | - | -228.2 | 639 | 900 | 1,193 |
| FCF margin | -2.28% | 1.92% | -2.25% | - | -0.67% | 1.74% | 1.84% | 2.07% |
| FCF Conversion (EBITDA) | - | 51.95% | - | - | - | 40.26% | 43.93% | 49.98% |
| FCF Conversion (Net income) | - | 159.33% | - | - | - | 153.24% | 170.78% | 134.5% |
| Dividend per Share 2 | 0.0510 | - | 0.0860 | - | - | 0.0270 | 0.0420 | - |
| Announcement Date | 2/25/20 | 3/1/21 | 3/23/22 | 3/1/23 | 3/3/24 | - | - | - |
1EGP in Million2EGP
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q2 | 2022 Q3 |
|---|---|---|
| Net sales 1 | 4,914 | 5,550 |
| EBITDA | - | - |
| EBIT 1 | - | 161.8 |
| Operating Margin | - | 2.92% |
| Earnings before Tax (EBT) | - | - |
| Net income 1 | 29.64 | 30.99 |
| Net margin | 0.6% | 0.56% |
| EPS | - | - |
| Dividend per Share | - | - |
| Announcement Date | 8/14/22 | 11/15/22 |
1EGP in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 921 | 943 | 1,817 | 3,362 | 3,687 | 3,649 | 3,442 | 3,265 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 1.227 x | 1.368 x | 2.156 x | 4.048 x | 2.575 x | 2.299 x | 1.68 x | 1.368 x |
| Free Cash Flow 1 | -378 | 358 | -488 | - | -228 | 639 | 900 | 1,193 |
| ROE (net income / shareholders' equity) | 33.1% | 18.8% | 22.3% | 12.7% | 15.8% | 24.1% | 24.6% | 26.7% |
| ROA (Net income/ Total Assets) | 4.97% | 2.95% | 3.07% | 1.43% | 1.36% | - | - | - |
| Assets 1 | 6,615 | 7,626 | 10,267 | 12,074 | 15,707 | - | - | - |
| Book Value Per Share 2 | 1.010 | 1.220 | 1.120 | 1.250 | 1.440 | 1.660 | 2.130 | 3.100 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 353 | 230 | 148 | 798 | 354 | 317 | 367 | 413 |
| Capex / Sales | 2.13% | 1.23% | 0.68% | 3.59% | 1.04% | 0.87% | 0.75% | 0.72% |
| Announcement Date | 2/25/20 | 3/1/21 | 3/23/22 | 3/1/23 | 3/3/24 | - | - | - |
1EGP in Million2EGP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.55
EGP
Average target price
4.843
EGP
Spread / Average Target
+89.93%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -18.79% | 54.04M | |
| -38.94% | 13.74B | |
| -37.47% | 10.13B | |
| -16.27% | 7.82B | |
| -0.74% | 5.82B | |
| -15.56% | 5.65B | |
| -4.23% | 4.6B | |
| +67.88% | 4.35B | |
| -8.77% | 3.79B | |
| -23.69% | 3.02B |
- Stock Market
- Equities
- ISPH Stock
- Financials Ibnsina Pharma
